Literature DB >> 19418267

Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.

F Geurs1, S Vandewaeter, S Ponette, J Ponette, S Knape, P Demetter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19418267     DOI： 10.1007/s12029-009-9060-4

Source DB:  PubMed          Journal:  J Gastrointest Cancer


× No keyword cloud information.
  14 in total

1.  Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites.

Authors:  C Twelves; R Glynne-Jones; J Cassidy; J Schüller; T Goggin; B Roos; L Banken; M Utoh; E Weidekamm; B Reigner
Journal:  Clin Cancer Res       Date:  1999-07       Impact factor: 12.531

2.  Synergistic antitumor activity of capecitabine in combination with irinotecan.

Authors:  Shousong Cao; Farukh A Durrani; Youcef M Rustum
Journal:  Clin Colorectal Cancer       Date:  2005-01       Impact factor: 4.481

3.  Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study.

Authors:  Timothy W Synold; Chris H Takimoto; James H Doroshow; David Gandara; Sridhar Mani; Scot C Remick; Daniel L Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz Josef Lenz; Martin Graham; Jeffrey Longmate; Bennett M Kaufman; Percy Ivy
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

4.  Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.

Authors:  Nicolas Moosmann; Dorit Laessig; Henrik Jakob Michaely; Christoph Schulz; Volker Heinemann
Journal:  Onkologie       Date:  2007-09-21

5.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

6.  Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

Authors:  D Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; C A Topham; L Awad; C Jacques; P Herait
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.

Authors:  P Rougier; E Van Cutsem; E Bajetta; N Niederle; K Possinger; R Labianca; M Navarro; R Morant; H Bleiberg; J Wils; L Awad; P Herait; C Jacques
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

8.  A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.

Authors:  A P Venook; C Enders Klein; G Fleming; D Hollis; C G Leichman; R Hohl; J Byrd; D Budman; M Villalona; J Marshall; G L Rosner; J Ramirez; H Kastrissios; M J Ratain
Journal:  Ann Oncol       Date:  2003-12       Impact factor: 32.976

9.  Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group.

Authors:  James H Doroshow; Timothy W Synold; David Gandara; Sridhar Mani; Scot C Remick; Daniel Mulkerin; Anne Hamilton; Sunil Sharma; Ramesh K Ramanathan; Heinz Josef Lenz; Martin Graham; Jeffrey Longmate; Chris H Takimoto; Percy Ivy
Journal:  Semin Oncol       Date:  2003-08       Impact factor: 4.929

10.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321
View more
  2 in total

1.  Weekly cisplatin may reverse liver dysfunction and jaundice caused by diffuse liver metastases of solid tumors.

Authors:  M Gabrovska; F Geurs; S Ponette; J Ponette; K Bulte; L Derveaux; I Kempeneers
Journal:  Hepat Med       Date:  2009-10-30

2.  Raltitrexed Inhibits HepG2 Cell Proliferation via G0/G1 Cell Cycle Arrest.

Authors:  Hongwei Zhao; Yubao Zhang; Jianmin Sun; Chao Zhan; Liang Zhao
Journal:  Oncol Res       Date:  2016       Impact factor: 5.574
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.